[1]张敬法,赵珍珍.湿性年龄相关性黄斑变性发病机制及治疗[J].眼科新进展,2022,42(2):085-98.[doi:10.13389/j.cnki.rao.2022.0019]
　ZHANG Jingfa,ZHAO Zhenzhen.Pathogenesis and treatment of wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2022,42(2):085-98.[doi:10.13389/j.cnki.rao.2022.0019]
点击复制

湿性年龄相关性黄斑变性发病机制及治疗/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年2期
页码:
085-98
栏目:
述评
出版日期:
2022-02-05

文章信息/Info

Title:
Pathogenesis and treatment of wet age-related macular degeneration
作者:
张敬法; 赵珍珍
200080　上海市，上海市第一人民医院眼科
Author(s):
ZHANG Jingfa; ZHAO Zhenzhen
Department of Ophthalmology,Shanghai General Hospital(Shanghai First People’s Hospital),Shanghai Jiao Tong University,School of Medicine,Shanghai 200080,China
关键词:
湿性年龄相关性黄斑变性; 黄斑区新生血管; 血管内皮生长因子; 抗血管内皮生长因子治疗; 纤维化
Keywords:
wet age-related macular degeneration;  macular neovascularization;  vascular endothelial growth factor;  anti-vascular endothelial growth factor therapy;  fibrosis
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2022.0019
文献标志码:
A
摘要:
湿性年龄相关性黄斑变性（AMD）是导致老年人视力受损甚至失明的重要原因，以黄斑区新生血管为主要病理特征，其发病与年龄、环境、遗传、氧化应激、脂质代谢、免疫机制等多因素相关。血管内皮生长因子（VEGF）已被证实是导致湿性AMD的重要因子。因此，抗VEGF药物是湿性AMD治疗领域中里程碑性的进展，但该治疗方法仍有诸多不足，如需要多次注射、部分患者对治疗应答欠佳甚至无应答、可能发生进行性纤维化等并发症。目前，许多新药正在被开发用来解决现有抗VEGF药物治疗的弊端。通过检索国内外相关文献及报道，我们对湿性AMD的分型、发病机制、治疗等的研究进展进行述评。
Abstract:
Wet age-related macular degeneration (wet AMD) is the main cause of visual impairment and even blindness in the elderly, with the primary pathological symptom of macular neovascularization. The pathogenesis of wet AMD is related to many factors, including age, environment, genetics, oxidative stress, lipid metabolism, and immunological mechanisms. Vascular endothelial growth factor (VEGF) has been proven to be a key factor that contributes to wet AMD. Therefore, the development of anti-VEGF drugs served as a milestone in treating wet AMD. However, current anti-VEGF drugs still have drawbacks, such as the need for multiple injections, lack of efficiency or even unresponsiveness in certain patients, and possible complications like progressive fibrosis. Currently, many new drugs are being developed to overcome the shortcomings of the existing anti-VEGF therapies. By searching relevant literature and reports, in this work we summarized and commented on the recent advancements in the classification, pathogenesis, and treatment of wet AMD.

参考文献/References:

［1］　SPAIDE R F,GJ J,SARRAF D,FREUND K B,SADDA S R,STAURENGHI G,et al.Consensus nomenclature for reporting neovascular age-related macular degeneration data:consensus on neovascular age-related macular degeneration nomenclature study group［J］.Ophthalmology,2020,127(5):616-636.
［2］　METTU P S,ALLINGHAM M J,COUSINS S W.Incomplete response to anti-VEGF therapy in neovascular AMD:exploring disease mechanisms and therapeutic opportunities［J］.Prog Retin Eye Res,2021,82:100906.
［3］　GILLIES M C,HUNYOR A P,ARNOLD J J,GUYMER R H,WOLF S,PECHEUR F L,et al.Macular atrophy in neovascular age-related macular degeneration:a randomized clinical trial comparing ranibizumab and aflibercept(RIVAL study)［J］.Ophthalmology,127(2):198-210.
［4］　DANIEL E,TOTH C A,GRUNWALD J E,GLENN J,MARTIN D F,FINE S L,et al.Risk of scar in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology,2014,121(3):656-666.
［5］　SINGER M A,AWH C C,SADDA S V,FREEMAN W R,ANTOSZYK A N,WONG P,et al.HORIZON:an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration［J］.Ophthalmology,2012,119(6):1175-1183.
［6］　ROFAGHA S,BHISITKUL R B,BOYER D S,SADDA S R,ZHANG K,SEVEN U G.Seven-year outcomes in ranibizumab-treated patients in ANCHOR,MARINA,and HORIZON:a multicenter cohort study(seven-up)［J］.Ophthalmology,2013,120(11):2292-2299.
［7］　WONG W L,SU X,LI X,CHEUNG C M,KLEIN R,CHENG C Y,et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040:a systematic review and meta-analysis［J］.Lancet Glob Health,2014,2(2):e106-e116.
［8］　ROH M,SELIVANOVA A,SHIN H J,MILLER J W,JACKSON M L.Visual acuity and contrast sensitivity are two important factors affecting vision-related quality of Life in advanced age-related macular degeneration［J］.PLoS One,2018,13(5):e0196481.
［9］　DOLZ-MARCO R,PHASUKKIJWATANA N,SARRAF D,FREUND K B.Regression of type 2 neovascularization into a type 1 pattern after intravitreal anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration［J］.Retina,2017,37(2):222-233.
［10］　JACKSON T L,DUGEL P,BEBCHUK J D,SMITH K R,PETRARCA R,SLAKTER J S,et al.Epimacular brachytherapy for neovascular age-related macular degeneration(CABERNET):fluorescein angiography and optical coherence tomography［J］.Ophthalmology,2013,120(8):1597-1603.
［11］　TENBROCK L,WOLF J,BONEVA S,SCHLECHT A,AGOSTINI H,WIEGHOFER P,et al.Subretinal fibrosis in neovascular age-related macular degeneration:current concepts,therapeutic avenues,and future perspectives［J］.Cell Tissue Res,2021.［Online ahead of print］(doi:10.1007/s00441-021-03514-8).
［12］　MYERS C E,KLEIN B E,GANGNON R,SIVAKUMARAN T A,IYENGAR S K,KLEIN R.Cigarette smoking and the natural history of age-related macular degeneration:the Beaver Dam Eye Study［J］.Ophthalmology,2014,121(10):1949-1955.
［13］　张志诚.吸烟对年龄相关性黄斑变性发生和发展的影响［J］.中华实验眼科杂志,2021,39(1):93-96.
ZHANG Z C.Influence of smoking on the occurrence and development of age-related macular degeneration［J］.Chin J Exp Ophthalmol,2021,39(1):93-96.
［14］　DETARAM H D,JOACHIM N,LIEW G,VU K V,BURLUTSKY G,MITCHELL P,et al.Smoking and treatment outcomes of neovascular age-related macular degeneration over 12 months［J］.Br J Ophthalmol,2020,104(7):893-898.
［15］　王蒙,梁凤鸣,王莉,黎红梅,陈涛.湿性年龄相关性黄斑变性危险因素的研究进展［J］.国际眼科杂志,2018,18(9):1604-1607.
WANG M,LIANG F M,WANG L,LI H M,CHEN T.Research progress on risk factors of wet age-related macular degeneration［J］.Int Eye Sci,2018,18(9):1604-1607.
［16］　MARNEROS A G,FAN J,YOKOYAMA Y,GERBER H P,FERRARA N,CROUCH R K,et al.Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function［J］.Am J Pathol,2005,167(5):1451-1459.
［17］　KURIHARA T,WESTENSKOW P D,BRAVO S,AGUILAR E,FRIEDLANDER M.Brief report targeted deletion of VEGFA in adult mice induces vision loss［J］.J Clin Invest,2012,122(11):4213-4217.
［18］　CAMPOCHIARO P A.Molecular pathogenesis of retinal and choroidal vascular diseases［J］.Prog Retin Eye Res,2015,49:67-81.
［19］　RICCI F,BANDELLO F,NAVARRA P,STAURENGHI G,STUMPP M,ZARBIN M.Neovascular age-related macular degeneration:therapeutic management and new-upcoming approaches［J］.Int J Mol Sci,2020,21(21):8242.
［20］　SIMONS M,GORDON E,CLAESSON-WELSH L.Mechanisms and regulation of endothelial VEGF receptor signalling［J］.Nat Rev Mol Cell Biol,2016,17(10):611-625.
［21］　ABOKYI S,TO C H,LAM T T,TSE D Y.Central role of oxidative stress in age-related macular degeneration:evidence from a review of the molecular mechanisms and animal models［J］.Oxid Med Cell Longev,2020,2020:7901270.
［22］　WATERS S B,ZHOU C,NGUYEN T,ZELKHA R,LEE H,KAZLAUSKAS A,et al.VEGFR2 trafficking by KIF13B is a novel therapeutic target for wet age-related macula r degeneration［J］.Invest Ophthalmol Vis Sci,2021,62(2):5.
［23］　UEMURA A,FRUTTIGER M,D’AMORE P A,DE FALCO S,JOUSSEN A M,SENNLAUB F,et al.VEGFR1 signaling in retinal angiogenesis and microinflammation［J］.Prog Retin Eye Res,2021,84:100954.
［24］　HERNNDEZ-ZIMBRN L F,ZAMORA-ALVARADO R,OCHOA-DE L L,VELEZ-MONTOYA R,ZENTENO E,GULIAS-CAIZO R,et al.Age-related macular degeneration:new paradigms for treatment and management of AMD［J］.Oxid Med Cell Longev,2018,2018:8374647.
［25］　HUSSAIN R M,NEIWEEM A E,KANSARA V,HARRIS A,CIULLA T.Tie-2/angiopoietin pathway modulation as a therapeutic strategy for retinal disease［J］.Expert Opin Investig Drugs,2019,28(10):861-869.
［26］　WOLF A,LANGMANN T.Anti-VEGF-A/ANG2 combotherapy limits pathological angiogenesis in the eye:a replication study［J］.EMBO Mol Med,2019,11(5):e10362.
［27］　NG D S,YIP Y W,BAKTHAVATSALAM M,CHEN L J,NG T K,LAI T Y,et al.Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation［J］.Sci Rep,2017,7:45081.
［28］　SHI X,GUO L W,SEEDIAL S M,SI Y,WANG B,TAKAYAMA T,et al.TGF-β/Smad3 inhibit vascular smooth muscle cell apoptosis through an autocrine signaling mechanism involving VEGF-A［J］.Cell Death Dis,2014,5(7):e1317.
［29］　WANG X,MA W,HAN S,MENG Z,ZHAO L,YIN Y,et al.TGF-β participates choroid neovascularization through Smad2/3-VEGF/TNF-α signaling in mice with laser-induced wet age-related macular degeneration［J］.Sci Rep,2017,7(1):9672.
［30］　WANG K,LI H,SUN R,LIU C,LUO Y,FU S,et al.Emerging roles of transforming growth factor β signaling in wet age-related macular degeneration［J］.Acta Biochim Biophys Sin(Shanghai),2019,51(1):1-8.
［31］　SHU D Y,BUTCHER E,SAINT-GENIEZ M.EMT and EndMT:emerging roles in age-related macular degeneration［J］.Int J Mol Sci,2020,21(12):4271.
［32］　LITTLE K,LLORIN-SALVADOR M,TANG M,DU X,MARRY S,CHEN M,et al.Macrophage to myofibroblast transition contributes to subretinal fibrosis secondary to neovascular age-related macular degeneration［J］.J Neuroinflammation,2020,17(1):355.
［33］　OLADIPUPO S S,SMITH C,SANTEFORD A,PARK C,SENE A,WILEY L A,et al.Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis［J］.Proc Natl Acad Sci U S A,2014,111(37):13379-13384.
［34］　DOLIVO D M,LARSON S A,DOMINKO T.Fibroblast growth factor 2 as an antifibrotic:antagonism of myofibroblast differentiation and suppression of Pro-Fibrotic gene expression［J］.Cytokine Growth Factor Rev,2017,38:49-58.
［35］　FUNK M,KARL D,GEORGOPOULOS M,BENESCH T,SACU S,POLAK K,et al.Neovascular age-related macular degeneration:intraocular cytokines and growth factors and the influence of therapy with ranibizumab［J］.Ophthalmology,2009,116(12):2393-2399.
［36］　STRITTMATTER K,POMEROY H,MARNEROS A G.Targeting platelet-derived growth factor receptor β(+) scaffold formation inhibits choroidal neovascularization［J］.Am J Pathol,2016,186(7):1890-1899.
［37］　TOOMEY C B,JOHNSON L V,BOWES R C.Complement factor H in AMD:bridging genetic associations and pathobiology［J］.Prog Retin Eye Res,2018,62:38-57.
［38］　KATO Y,OGUCHI Y,OMORI T,SHINTAKE H,TOMITA R,KASAI A,et al.Complement activation products and cytokines in pachychoroid neovasculopathy and neovascular age-related macular degeneration［J］.Invest Ophthalmol Vis Sci,2020,61(13):39.
［39］　WU J,SUN X.Complement system and age-related macular degeneration:drugs and challenges［J］.Drug Des Devel Ther,2019,13:2413-2425.
［40］　JENSEN E G,JAKOBSEN T S,THIEL S,ASKOU A L,CORYDON T J.Associations between the complement system and choroidal neovascularization in wet age-related macular degeneration［J］.Int J Mol Sci,2020,21(24):9752.
［41］　SARMA J V,WARD P A.The complement system［J］.Cell Tissue Res,2011,343(1):227-235.
［42］　COUGHLIN B,SCHNABOLK G,JOSEPH K,RAIKWAR H,KUNCHITHAPAUTHAM K,JOHNSON K,et al.Connecting the innate and adaptive immune responses in mouse choroidal neovascularization via the anaphylatoxin C5a and γδ T- cells［J］.Sci Rep,2016,6:23794.
［43］　GUO H T,CALLAWAY J B,TING J P.Inflammasomes:mechanism of action,role in disease,and therapeutics［J］.Nat Med,2015,21(7):677-687.
［44］　DOYLE S L,CAMPBELL M,OZAKI E,SALOMON R G,MORI A,KENNA P F,et al.NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components［J］.Nat Med,2012,18(5):791-798.
［45］　GAO J,LIU R T,CAO S,CUI J Z,WANG A,TO E,et al.NLRP3 inflammasome:activation and regulation in age-related macular degeneration［J］.Mediators Inflamm,2015,2015 :690243.
［46］　KAUPPINEN A,PATERNO J J,BLASIAK J,SALMINEN A,KAARNIRANTA K.Inflammation and its role in age-related macular degeneration［J］.Cell Mol Life Sci,2016,73(9):1765-1786.
［47］　MALSY J,ALVARADO A C,LAMONTAGNE J O,STRITTMATTER K,MARNEROS A G.Distinct effects of complement and of NLRP3- and non-NLRP3 inflammasomes for choroidal neovascularization［J］.Elife,2020,9:e60194.
［48］　NUSSENBLATT R B,LIU B,WEI L,SEN H N.The immunological basis of degenerative diseases of the eye［J］.Int Rev Immunol,2013,32(1):97-112.
［49］　XU Y,CUI K,LI J,TANG X,LIN J,LU X,et al.Melatonin attenuates choroidal neovascularization by regulating macrophage/microglia polarization via inhibition of RhoA/ROCK signaling pathway［J］.J Pineal Res,2020,69(1):e12660.
［50］　YANG Y,LIU F,TANG M,YUAN M,HU A,ZHAN Z,et al.Macrophage polarization in experimental and clinical choroidal neovascularization［J］.Sci Rep,2016,6:30933.
［51］　DROHO S,CUDA C M,PERLMAN H,LAVINE J A.Macrophage-derived interleukin-6 is necessary and sufficient for choroidal angiogenesis［J］.Sci Rep,2021,11(1):18084.
［52］　ZHOU Y,ZENG J,TU Y,LI L,DU S,ZHU L,et al.CSF1/CSF1R-mediated crosstalk between choroidal vascular endothelial cells and macrophages promotes choroidal neovascularization［J］.Invest Ophthalmol Vis Sci,2021,62(3):37.
［53］　GOLESTANEH N,CHU Y,XIAO Y Y,STOLERU G L,THEOS A C.Dysfunctional autophagy in RPE,a contributing factor in age-related macular degeneration［J］.Cell Death Dis,2017,8(1):e2537.
［54］　PARK T K,LEE S H,CHOI J S,NAH S K,KIM H J,PARK H Y,et al.Adeno-associated viral vector-mediated mTOR inhibition by short hairpin RNA suppresses laser-induced choroidal neovascularization［J］.Mol Ther Nucleic Acids,2017,8:26-35.
［55］　YANG J Y,MADRAKHIMOV S B,AHN D H,CHANG H S,JUNG S J,NAH S K,et al.mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV［J］.Cell Commun Signal,2019,17(1):64.
［56］　XIE L,JI X,TU Y,WANG K,ZHU L,ZENG X,et al.MLN4924 inhibits hedgehog signaling pathway and activates autophagy to alleviate mouse laser-induced choroidal neovascularization lesion［J］.Biomed Pharmacother,2020,130:110654.
［57］　KIM S Y,KAMBHAMPATI S P,BHUTTO I A,MCLEOD D S,LUTTY G A,KANNAN R M.Evolution of oxidative stress,inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model［J］.Exp Eye Res,2021,203:108391.
［58］　BHATWADEKAR A D,KANSARA V,LUO Q,CIULLA T.Anti-integrin therapy for retinovascular diseases［J］.Expert Opin Investig Drugs,2020,29(9):935-945.
［59］　吴晶,杨长平,刘锦荣,罗燕,徐鹰,钟佳宁,等.外泌体与眼科疾病相关性的研究［J］.国际眼科纵览,2018,42(6):388-392.
WU J,YANG C P,LIU J R,LUO Y,XU Y,ZHONG J N,et al.Research on exosomes and eye diseases［J］.Int Rev Ophthalmol,2018,42(6):388-392.
［60］　梁颖慧,陈一文,崔瑶.脂质代谢与年龄相关性黄斑变性［J］.国际眼科纵览,2021,45(4):346-350.
LIANG Y H,CHEN Y W,CUI Y.Lipid metabolism and age-related macular degeneration［J］.Int Rev Opthalmol,2021,45(4):346-350.
［61］　SUPURAN C T.Agents for the prevention and treatment of age-related macular degeneration and macular edema:a literature and patent review［J］.Expert Opin Ther Pat,2019,29(10):761-767.
［62］　Group Research CATT,MARTIN D F,MAGUIRE M G,YING G S,GRUNWALD J E,FINE S L,et al.Ranibizumab and bevacizumab for neovascular age-related macular degeneration［J］.N Engl J Med,2011,364(20):1897-1908.
［63］　MITCHELL P,KOROBELNIK J F,LANZETTA P,HOLZ F G,PRNTE C,SCHMIDT-ERFURTH U,et al.Ranibizumab(lucentis) in neovascular age-related macular degeneration:evidence from clinical trials［J］.Br J Ophthalmol,2010,94(1):2-13.
［64］　FDA approves Roche ’ s Susvimo,a first-of-its-kind therapeutic approach for neovascular or “ wet ” age-related macular degeneration(nAMD)［EB/OL］.(2021-10-22)［2022-01-04］.https://www.roche.com/investors/updates/inv-update-2021-10-22b.htm.
［65］　HOLEKAMP N M,CAMPOCHIARO P A,CHANG M,MILLER D,PIERAMICI D,ADAMIS A P,et al.Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration［J］.Ophthalmology,2021.［Online ahead of print］(doi:10.1016/j.ophtha.2021.09.016).
［66］　NGUYEN Q D,DAS A,DO D V,DUGEL P,GOMES A,HOLZ F G,et al.Brolucizumab:evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration［J］.Ophthalmology,2020,127(7):963-976.
［67］　DUGEL P,SINGH R P,KOH A,OGURA Y,WEISSGERBER G,GEDIF K,et al.HAWK and HARRIER:ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration［J］.Ophthalmology,2021,128(1):89-99.
［68］　MONS J,SRIVASTAVA S K,GJ J,TADAYONI R,ALBINI T,KAISER P K,et al.Risk of inflammation,retinal vasculitis,and retinal occlusion-related events with brolucizumab:post Hoc review of HAWK and HARRIER［J］.Ophthalmology,2021,128(7):1050-1059.
［69］　SARWAR S,CLEARFIELD E,SOLIMAN M K,SADIQ M,BALDWIN A J,HANOUT M,et al.Aflibercept for neovascular age-related macular degeneration［J］.Cochrane Database Syst Rev,2016,2(10):CD011346.
［70］　LIU K,SONG Y,XU G,YE J,WU Z,LIU X,et al.Conbercept for treatment of neovascular age-related macular degeneration:results of the randomized phase 3 Phoenix study［J］.Am J Ophthalmol,2019,197:156-167.
［71］　金明,陈有信.中成药治疗年龄相关性黄斑变性（湿性）临床应用指南（2020 年）［J］.中国中西医结合杂志,2021,41(2):151-156.
JIN M,CHEN Y X.Guidelines for the clinical application of Chinese patent medicines in the treatment of age-related macular degeneration(wet)(2020) ［J］.Chin J Int Med,2021,41(2):151-156.
［72］　JIN M,DAI H,ZHANG X,WANG Y,HAN M,ZHANG H,et al.A traditional Chinese patent medicine ZQMT for neovascular age-related macular degeneration:a multicenter randomized clinical trial［J］.Curr Mol Med,2018,18(9):622-629.
［73］　LI Y,LIANG L,SNELLINGEN T,XU K,GAO Y,ZHANG F,et al.Mingjing granule,a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration:study protocol for a randomized controlled trial［J］.Trials,2021,22(1):69.
［74］　PARRAVANO M,TEDESCHI M,MANCA D,COSTANZO E,DI RENZO A,GIORNO P,et al.Effects of macuprev? supplementation in age-related macular degeneration:a double-blind randomized morpho-functional study along 6 months of follow-up［J］.Adv Ther,2019,36(9):2493-2505.
［75］　GARCA-LAYANA A,RECALDE S,HERNANDEZ M,ABRALDES M J,NASCIMENTO J,HERNNDEZ-GALILEA E,et al.A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration［J］.Nutrients,2021,13(4):1253.
［76］　DHARAMDASANI D H,MITCHELL P,RUSSELL J,BURLUTSKY G,LIEW G,GOPINATH B.Dietary zinc intake is associated with macular fluid in neovascular age-related macular degeneration［J］.Clin Exp Ophthalmol,2020,48(1):61-68.
［77］　KAARNIRANTA K,PAWLOWSKA E,SZCZEPANSKA J,JABLKOWSKA A,BASIAK J.Can vitamin D protect against age-related macular degeneration or slow its progression?［J］.Acta Biochim Pol,2019,66(2):147-158.
［78］　MATAS-PREZ D,GARCA-MONTALVO I A.Fatty acids and lipid derivatives protecting photooxidative attack in age-related macular degeneration［J］.J Oleo Sci,2021,70(4):453-458.
［79］　AMMAR M J,HSU J,CHIANG A,HO A C,REGILLO C D.Age-related macular degeneration therapy:a review［J］.Curr Opin Ophthalmol,2020,31(3):215-221.
［80］　Phase 2b clinical trial for the treatment of wet AMD in which OPT-302 administered in combination with the VEGF-A inhibitor Lucentis?［EB/OL］.(2021-01-12)［2021-09-10］.https://opthea.com/wet-amd-clinical-trial.
［81］　SAMANTA A,AZIZ A,JHINGAN M,SINGH S R,KHANANI A M,CHHABLANI J.Emerging therapies in neovascular age-related macular degeneration in 2020［J］.Asia Pac J Ophthalmol(Phila),2020,9(3):250-259.
［82］　TERRY M.Allergan/AbbVie’s macular degeneration drug rejected by FDA［EB/OL］.(2020-06-26)［2021-11-01］.https://www.biospace.com/article/fda-reject-s-allergan-s-abicipar-pegol-for-age-related-macular-degeneration.
［83］　REN X,LI J,XU X,WANG C,CHENG Y.IBI302,a promising candidate for AMD treatment,targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys［J］.Exp Eye Res,2016,145:352-358.
［84］　信达生物.抗VEGF-补体双靶点药物 IBI302用于新生血管性年龄相关性黄斑变性的II期临床研究完成首例患者给药［EB/OL］.(2021-04-29)［2021-10-10］.https://www.prnasia.com/story/316916-1.shtml.
INNOVENT BIOLOGICS.Innovent announces first patient dosed in the phase 2 clinical trial of IBI302,a first-in-class ophthalmic anti-vegf and anti-complement bispecific fusion protein for neovascular age-related macular degeneration［EB/OL］.(2021-04-29)［2021-10-10］.https://en.prnasia.com/releases/apac/innovent-announces-first-patient-dosed-in-the-phase-2-clinical-trial-of-ibi302-a-first-in-class-ophthalmic-anti-vegf-and-anti-complement-bispecific-fusion-protein-for-neovascular-age-related-macular-degeneration-316920.shtml.
［85］　JAFFE G J,CIULLA T,CIARDELLA A P,DEVIN F,DUGEL P,EANDI C M,et al.Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration:a phase IIb,multicenter,randomized controlled trial［J］.Ophthalmology,2017,124(2):224-234.
［86］　REGENERON PHARMACEUTICALS.Study of intravitreal REGN2176-3 in participants with neovascular(“wet”) age-related macular degeneration(AMD)(CAPELLA)［EB/OL］.(2020-10-26)［2021-10-10］.https://clinicaltrials.gov/show/NCT02418754,2015(PG-).
［87］　PARRAVANO M,COSTANZO E,SCONDOTTO G,TRIFIR G,VIRGILI G.Anti-VEGF and other novel therapies for neovascular age-related macular degeneration:an update［J］.BioDrugs,2021,35(6):673-692.
［88］　ADAMS C M,ANDERSON K,ARTMAN G,BIZEC J C,CEPEDA R,ELLIOTT J,et al.The discovery of N-(1-Methyl-5-(trifluoromethyl)-1h-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide(acrizanib),a VEGFR-2 inhibitor specifically designed for topical ocular delivery,as a therapy for neovascular age-related macular degeneration［J］.J Med Chem,2018,61(4):1622-1635.
［89］　COHEN M N,O’SHAUGHNESSY D,FISHER K,CERAMI J,AWH C C,SALAZAR D,et al.APEX:a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration［J］.Br J Ophthalmol,2021,105(5):716-722.
［90］　GRISHANIN R,VUILLEMENOT B,SHARMA P,KERAVALA A,GREENGARD J,GELFMAN C,et al.Preclinical evaluation of ADVM-022,a novel gene therapy approach to treating wet age-related macular degeneration［J］.Mol Ther,2019,27(1):118-129.
［91］　Adverum biotechnologies announces positive interim data from cohorts 1-4 from OPTIC phase 1 trial of ADVM-022 intravitreal gene therapy for wet AMD［EB/OL］.(2020-05-05)［2021-10-10］.https://www.biospace.com/article/releases/adverum-biotechnologies-announces-positive-interi m-data-from-cohorts-1-4-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet -amd/,:22.
［92］　LAI C C,WU W C,CHEN S L,XIAO X,TSAI T C,HUAN S J,et al.Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin［J］.Invest Ophthalmol Vis Sci,2001,42(10):2401-2407.
［93］　CAMPOCHIARO P A,LAUER A K,SOHN E H,MIR T A,NAYLOR S,ANDERTON M C,et al.Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration(GEM) study［J］.Hum Gene Ther,2017,28(1):99-111.
［94］　JIN Z B,GAO M L,DENG W L,WU K C,SUGITA S,MANDAI M,et al.Stemming retinal regeneration with pluripotent stem cells［J］.Prog Retin Eye Res,2019,69:38-56.
［95］　MANDAI M,KURIMOTO Y,TAKAHASHI M.Autologous induced stem-cell-derived retinal cells for macular degeneration［J］.N Engl J Med,2017,377(8):792-793.
［96］　MANDAI M,WATANABE A,KURIMOTO Y,HIRAMI Y,MORINAGA C,DAIMON T,et al.Autologous induced stem-cell-derived retinal cells for macular degeneration［J］.N Engl J Med,2017,376(11):1038-1046.

相似文献/References:

[1]施晨蕾 王亚冬.湿性年龄相关性黄斑变性患者光感受器细胞层变化与视力的相关性研究[J].眼科新进展,2013,33(11):000.
[2]肖昂,周琼.Aflibercept治疗湿性AMD和黄斑水肿的相关研究现状[J].眼科新进展,2014,34(6):598.[doi:10.13389/j.cnki.rao.2014.0165]
[3]蒋胜群,高自清,王剑锋,等.外周血淋巴细胞DNA损伤与湿性年龄相关性黄斑变性的关系[J].眼科新进展,2018,38(8):769.[doi:10.13389/j.cnki.rao.2018.0181]
　JIANG Sheng-Qun,GAO Zi-Qing,WANG Jian-Feng,et al.Relationship between the DNA damage of peripheral blood lymphocyte and wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2018,38(2):769.[doi:10.13389/j.cnki.rao.2018.0181]
[4]黄玉婷,李晓洁,郑香悦,等.湿性年龄相关性黄斑变性患者抗血管内皮生长因子治疗敏感性的影响因素：基于房水细胞因子分析[J].眼科新进展,2021,41(3):240.[doi:10.13389/j.cnki.rao.2021.0050]
　HUANG Yuting,LI Xiaojie,ZHENG Xiangyue,et al.Analysis of factors influencing the sensitivity of anti vascular endothelial growth factor therapy in patients with wet age-related macular degeneration based on aqueous humor cytokines[J].Recent Advances in Ophthalmology,2021,41(2):240.[doi:10.13389/j.cnki.rao.2021.0050]
[5]肇莉莉,王萍,孙连义,等.HTRA3基因对脉络膜新生血管和M2型巨噬细胞极化的影响[J].眼科新进展,2024,44(4):275.[doi:10.13389/j.cnki.rao.2024.0054]
　ZHAO Lili,WANG Ping,SUN Lianyi,et al.Effect of HtrA serine peptidase 3 gene on choroidal neovascularization and M2 macrophage polarization[J].Recent Advances in Ophthalmology,2024,44(2):275.[doi:10.13389/j.cnki.rao.2024.0054]
[6]张甜甜,李静,田珍.血小板源性生长因子在湿性年龄相关性黄斑变性新生血管及纤维化中的作用研究进展[J].眼科新进展,2024,44(5):410.[doi:10.13389/j.cnki.rao.2024.0080]
　ZHANG Tiantian,LI Jing,TIAN Zhen.Advances in the role of platelet-derived growth factor in neovascularisation and fibrosis in neovascular age-related macular degeneration[J].Recent Advances in Ophthalmology,2024,44(2):410.[doi:10.13389/j.cnki.rao.2024.0080]

备注/Memo

备注/Memo:
国家自然科学基金项目（编号：82171062）
更新日期/Last Update: 2022-02-05